Argentina Nuclear Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Argentina Nuclear Imaging Market Trends and Insights

Public Reimbursement Expansion for PET/CT Scans

The Programa Médico Obligatorio now covers PET/CT and gamma-camera oncology procedures without co-payments, removing a key affordability barrier and expanding access for lower-income populations. Procedure volumes in the Argentina nuclear imaging market are therefore rising at double-digit rates, particularly in provincial hospitals that previously limited advanced imaging due to budget constraints. The policy dovetails with national cancer initiatives that prioritize early detection and standardized follow-up protocols. Equipment utilization rates are climbing, prompting facilities to plan scanner upgrades within three years. Vendors offering flexible service contracts and remote diagnostics gain an edge because public hospitals must balance expanded demand with tight operating budgets.

Private-Sector Investment in Hybrid Imaging Centers

Currency-control reforms in late 2023 streamlined medical device imports, spurring private hospital groups to build dedicated PET/CT and SPECT/CT suites in major cities. These centers target affluent urban patients seeking concierge-style diagnostics and same-day reporting. Higher cash flows allow rapid adoption of AI reconstruction algorithms that cut scan times by up to 30%, lifting daily throughput. The Argentina nuclear imaging market thus benefits from a virtuous cycle of technology refresh and premium pricing. Domestic integrators such as INVAP partner with multinationals to supply turnkey facilities, embedding local support teams that mitigate peso volatility risks for investors.

Growing Oncology Caseload and Precision-Medicine Shift

Argentina recorded 130,878 new cancer diagnoses in 2020 and faces a projected 70% rise in per-capita cancer spending by 2050. This epidemiological pressure drives continuous demand for nuclear imaging in staging, therapy planning, and theranostics. The National Family Cancer Program promotes gene-panel testing that pairs with radiolabeled therapies, deepening tracer utilization. As tertiary centers expand molecular tumor boards, the Argentina nuclear imaging market gains visibility among oncologists who historically defaulted to CT or MRI. Vendors capable of offering both radiopharmaceuticals and cloud-based image analytics are increasingly preferred by multidisciplinary teams.

Installation of Domestic Mo-99 Production Reactor (RA-10)

RA-10 is 80% complete and scheduled for 2026 commissioning, with capacity to supply 20% of global Mo-99 requirements. Domestic isotope output slashes import lead times, stabilizes technetium-99m pricing, and lowers procedure cancellations tied to flight delays. INVAP’s supply agreements with 80 Argentine contractors also stimulate job creation and technology diffusion. Once operational, the reactor will add lutetium-177 production, establishing Argentina as a theranostics exporter to neighboring markets. The Argentina nuclear imaging industry consequently gains strategic autonomy that cushions it from forex volatility and geopolitical supply risks.

Peso Volatility Raising Imported Device Prices

Roughly 80% of scanners and cyclotrons are sourced abroad and invoiced in U.S. dollars; sharp peso depreciation balloons procurement budgets and prompts payment-term renegotiations. Revised import rules now stagger settlement over four months, straining cash flow for public buyers. Some provincial tenders have been postponed, temporarily tempering the Argentina nuclear imaging market’s equipment refresh pace. Vendors mitigate risk by quoting in pesos at forward-hedged rates or offering operating leases that shift currency exposure onto manufacturers. Local assembly initiatives under discussion could offset volatility over the medium term.

Short Half-Life Isotope Logistics Outside Buenos Aires

Technetium-99m and fluorine-18 decay rapidly, making timely distribution to remote provinces difficult. Flights into Patagonia can be disrupted by weather, extending transport times beyond viable radiochemical purity windows. Consequently, procedure cancellations reach 12% in winter months, constraining provincial scan volumes. Mobile generator technologies and regional cyclotron projects are proposed but remain unfunded. Until RA-10 derived supplies enable broader regional dispatch, geographic inequity will persist in the Argentina nuclear imaging market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Sustained Equipment Dominance and Isotope Upswing

Equipment accounted for 52.22% of the Argentina nuclear imaging market size in 2025, anchored by 389 SPECT and 42 PET scanners across public and private networks. Hospitals are cycling out first-generation gamma cameras, replacing them with SPECT/CT hybrids that support oncology staging and bone metastasis assessment. Vendors bundle five-year service contracts and AI upgrades, creating predictable cost structures that align with public-budget cycles. Local manufacturer INVAP supplies shielded hot cells and quality-control instruments, capturing niche demand and injecting domestic value into the supply chain.  

Radioisotopes, though presently smaller in revenue terms, are forecast to grow at 5.56% CAGR as RA-10 brings molybdenum-99, lutetium-177, and iodine-131 production in-country. Domestic supply eliminates flight-dependent logistics for imported isotopes, lowering costs and spurring utilization, which feeds back into higher tracer demand. Contract manufacturing opportunities emerge for Dioxitek and Tecnonuclear to export surplus isotopes to Chile, Uruguay, and Paraguay. Consequently, the product mix will tilt gradually toward consumables, generating recurring revenue streams and broadening the Argentina nuclear imaging market.

By Application: Cardiology Reigns While Neurology Accelerates

Cardiology retained 58.19% of Argentina nuclear imaging market share in 2025, driven by widespread uptake of SPECT myocardial perfusion imaging in tertiary hospitals. Rising obesity and diabetes prevalence sustains referral volumes, and new F-18 labeled perfusion tracers promise superior accuracy at lower doses. However, reimbursement bottlenecks and alternative CT modalities may temper long-term dominance.  

Neurology is set to expand at a 7.78% CAGR through 2031 as dementia screening becomes national public-health policy and alpha-synuclein tracers enter clinical trials. PET imaging with amyloid and tau agents detects preclinical Alzheimer’s disease, enabling timely therapeutic interventions. Provincial memory clinics integrate tele-neurology consults to broaden access, boosting tracer consumption outside Buenos Aires. Oncology, although not the fastest mover, benefits from theranostic rollout, ensuring stable double-digit tracer growth. This evolving mix underscores shifting clinical priorities and technological maturation within the Argentina nuclear imaging market.

By End User: Hospital Supremacy Meets Private-Center Momentum

Hospitals controlled 60.65% of 2025 revenues owing to integrated care pathways and captive inpatient populations. University hospitals serve as referral hubs for complex oncology and neurology cases, anchoring national training programs for technologists and radiopharmacists. Capital-budget allocations, though pressured by fiscal austerity, are partially offset by multilateral loans that earmark oncology equipment procurement.  

Diagnostic imaging centers, expanding at 5.93% CAGR, cater to insured middle-income patients who value shorter wait times and premium service. Chain operators deploy aggressive marketing and loyalty programs tied to employer health plans, diverting outpatient demand from public facilities. Many centers co-locate cyclotrons with radiopharmacies, enabling on-site F-18 production that circumvents transport constraints. Academic and research institutes remain niche users but play an outsized role in clinical trials that seed future tracer adoption across the Argentina nuclear imaging market.

Geography Analysis

Buenos Aires Metropolitan Area concentrates nearly 70% of national scanner inventory, supported by dense specialist networks and proximity to isotope distribution nodes at Ezeiza International Airport. Flagship institutions such as Hospital de Clínicas and the Argentine Proton Therapy Centre anchor multimodality oncology programs, driving high daily throughput. Private centers leverage affluent demographics to sustain premium price points and early adoption of AI decision-support tools.  

Córdoba and Rosario form secondary hubs, boasting university hospitals that run accredited radiopharmacy programs and host CNEA-funded theranostic trials. These provinces benefit from highway connections that shorten isotope transit times, enabling reliable same-day tracer delivery. Expansion of mobile PET units further spreads access across peri-urban localities.  

Northern and southern provinces confront persistent capacity gaps due to sparse populations, challenging terrain, and limited specialist staffing. Technetium-99m generator exchanges occur only twice weekly, constraining scan scheduling flexibility. Telemedicine initiatives and planned mini-cyclotrons aim to shrink disparities, yet funding uncertainties slow deployment. Upon RA-10 start-up, CNEA intends to route isotopes via regional consolidation points, potentially reducing shipping times by up to 30%. As these logistics mature, provincial procedure volumes are expected to rise, broadening the geographic footprint of the Argentina nuclear imaging market.

Regulatory Landscape

Nuclear imaging in Argentina operates under a dual oversight model: the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) regulates imaging equipment and related medical technologies through its Registro de Productores y Productos de Tecnología Médica, while nuclear and radiological safety for facilities and radioactive materials is supervised by the Autoridad Regulatoria Nuclear (ARN) under the national nuclear activity framework (Law 24.804). In parallel, the Comisión Nacional de Energía Atómica (CNEA) supports R&D and clinical translation for radiotracers, including theranostic programs referenced in the market context.

For device compliance, ANMAT aligns with MERCOSUR technical regulations and has been transposing IMDRF/GRRP guidance into the national framework to standardize safety and performance expectations across medical devices. As AI and software become more embedded in dose optimization and workflow, ANMAT's Software as a Medical Device pathway (Regulation 9688/19) provides the approval and post-market basis for software used alongside PET/SPECT systems, complementing site-level radiation protection requirements enforced through ARN inspections.

Value Chain Analysis

The Argentina nuclear imaging value chain spans (1) radioisotope production and processing (CNEA-linked infrastructure and local players such as Dioxitek and Tecnonuclear, with the RA-10 reactor positioned in the report context as a step change for Mo-99 and other isotopes), (2) radiopharmacy compounding and kit preparation, (3) equipment sourcing and delivery (PET, SPECT, and hybrid systems that are predominantly imported), and (4) installation, service, uptime management, and clinical application support delivered by vendor subsidiaries and local channel partners. Downstream, hospitals and diagnostic imaging centers convert these inputs into reimbursed procedures, while logistics performance, particularly for short half-life tracers, materially influences realized scan capacity outside Buenos Aires.

On the equipment and commercial services layer, multinationals such as GE HealthCare, Siemens Healthineers, and Canon operate locally through Argentine entities and distributor networks, with value captured through financing, multiyear maintenance contracts, applications training, and remote support. A visible feature of the market setup is reliance on authorized local partners for regulated healthcare products and servicing in-country. This structure helps hospitals and private centers manage import complexity, lifecycle costs, and compliance needs while keeping high-tech manufacturing largely offshore.

Market Opportunities and Future Outlook

A central opportunity is the consumables and service stack that supports rising PET/CT and hybrid utilization. Stable, in-country radioisotope availability and integrated distribution can translate into fewer cancellations and more predictable scheduling, especially outside Buenos Aires where short half-life logistics constrain throughput in the report context. The May 31, 2026 Lineamientos de la Politica Nuclear Argentina 2026 and the Secretaría de Asuntos Nucleares created by Decree 866/2025 provide an explicit policy anchor that prioritizes commercial management of radioisotopes and high-value-added exports. This reinforces the business case for scaling radiopharmacy capacity, quality control infrastructure, and compliant cold-chain and last-mile delivery.

A second opportunity cluster is financing-enabled equipment refresh and digital and AI upgrades across public and private providers. Market evidence in the report context points to financing as a key execution variable for imaging projects, and Siemens Healthineers presence (around 1,200 installed units in Argentina, per local reporting) highlights the installed-base runway for replacements, hybrid conversions, and software-led throughput gains. As AI dose-optimization and reconstruction move into routine procurement conversations, vendors and local integrators that bundle scanners, software, service, and long-tenor financing can address dual constraints of budget pressure and aging fleets, while widening access beyond the main urban hubs.